<DOC>
	<DOCNO>NCT02094521</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate optimal dose condition GLP-1 analogue NNC0113-0987 administer orally healthy male subject .</brief_summary>
	<brief_title>Evaluation Optimal Dosing Conditions GLP-1 Analogue NNC0113-0987 When Administered Orally Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Male age 18 55 year ( inclusive ) time sign informed consent Good general health base medical history , physical examination , result vital sign , electrocardiogram laboratory safety test perform screen visit , judge investigator Body mass index ( BMI ) 18.5 29.9 kg/m^2 ( inclusive ) History , presence , cancer , diabetes clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder , judge investigator Blood pressure 140 mmHg systolic and/or 90 mmHg diastolic pulse 90 beat per minute screen visit Smoking 5 cigarette equivalent per day ( include use nicotine substitute product ) History significant drug abuse , positive drug test screen visit Any blood draw excess 25 mL past month , donation blood plasma excess 400 mL within 3 month precede screen visit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>